New combo therapy hopes to boost immune attack on Hard-to-Treat melanoma
NCT ID NCT06784648
First seen Nov 19, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests a new drug called BI-1607 combined with two existing immunotherapies (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or cannot be removed. The goal is to see if adding BI-1607 helps the immune system better destroy cancer cells. About 35 adults whose melanoma worsened after prior treatment will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Universitatsmedizin Berlin
Berlin, Germany
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Sarah Cannon Research Institute UK
London, Greater London, W1G 6AD, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Hospital 12 de Octubre
Madrid, Spain
-
University Hospital Essen
Essen, Germany
-
University Hospital Heidelberg
Heidelberg, Germany
-
University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ)
Mannheim, Germany
-
Velindre Cancer Centre
Cardiff, Wales, CF14 2TL, United Kingdom
Conditions
Explore the condition pages connected to this study.